Table 3.

Correlation of clinical features across GEP-defined subgroups in training (TR) and test (TE) cohorts

	PR			LB			MS		HY		CD-1*		CD-2			MF
	TR	TE	P	TR	TE	P	TR	TE	TR	TE	TR	TE	TR	TE	P	TR	TE	P
B2M level of 339 nM or higher	66	61	NS	35	41	NS	30	29	27	36	36	33	42	41	NS	52	44	< .01
LDH level of 190 U/L or higher	48	56	NS	29	22	NS	26	38	26	18	36	17	40	29	NS	45	38	< .01
Albumin level of less than 35 g/L	55	39	.023	29	41	NS	55	67	38	44	32	17	30	35	NS	29	25	.033
Cytogenetic abnormalities	69	83	.021	19	44	< .01	48	50	41	44	45	17	12	12	NS	38	38	< .01
MR1 focal lesions, 3 or more	83	71	.044	30	21	NS	52	61	57	62	71	67	69	46	.001†	40	46	< .01

For the MS, HY, and MF groups, the P values were not significant; for the CD-1 group, the P values were not applicable. The total P represents the test for differences in the variable across the subgroups. This was performed on the mean of training and test set percentages. The total P was less than .01 for all groups. Values indicate the percentage of the total number of cases within each subgroup having the variable indicated. Statistical tests were performed for differences in the percentage of cases between the training and test sets.

NS indicates not significant.

^*Due to small number of CD-1 cases (n = 6) in the TT3 cohort, a statistical analysis was not performed. Differences were established by chi-square test.